Source facts
FDA issued an approval letter for SOGROYA on 2026-03-03. The source metadata identifies BLA 761156 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
SOGROYA — FDA Approval Letter (BLA 761156)
Issued to NOVO NORDISK INC. Application is approved as submitted.
Assyro regulatory brief
FreeWhat did FDA decide for SOGROYA?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: BLA 761156.
- 3Submission: supplement.
- 4Sponsor: NOVO NORDISK INC.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the SOGROYA approval letter
Is SOGROYA FDA approved?
This letter documents an FDA approval action: FDA approved BLA 761156 for SOGROYA, sponsored by NOVO NORDISK INC, on March 3, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is BLA 761156?
BLA 761156 is the application under which FDA issued this approval letter for SOGROYA to NOVO NORDISK INC. The letter is dated March 3, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.